bridion174-sugammadex(存儲(chǔ)版)
【正文】 ugammadex Manufacturer: Merck FDA Approval Date: December 15, 2020 Bridion174。 [package insert]. Bridion174。 [package insert]. Bridion174。18:99. ? Sugammadex achieved significantly faster recovery of T4/T1 ratio to pared with neostigmine after neuromuscular block with rocuronium ? Outliers and variability of recovery times were significantly lower following reversal with sugammadex Blobner M, et al. Eur J Anaesthesiol. 2020。18:99. Bridion174。18:99. ? Included: Adult patients scheduled for surgery under general anesthesia in the supine position ? 18 years old ? ASA class 1 to 3 ? Primary oute: Recovery time after reversal agent administration ? measured as train of four ratio (T4/T1) of Blobner M, et al. Eur J Anaesthesiol. 2020。 [package insert]. Bridion174。 Sugammadex Bridion174。 Sugammadex 2. Effectively educate patients on the purpose, proper use and potential adverse effects of Bridion174。 Sugammadex Drug Facts ? Mechanism of Action ? Cyclodextrin that forms a 1:1 plex with rocuronium and vecuronium ? This reduces the amount of free NMB agent in plasma ? In turn, the c
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號(hào)-1